TB-500

Research Use Only: This page is for research and educational purposes only. It does not provide medical advice, treatment instructions, or guaranteed outcome claims.

What Is TB-500?

If your query is what is tb-500, the practical answer is: TB-500 is a synthetic peptide fragment corresponding to the active region (amino acids 17-23) of thymosin beta-4, a naturally occurring 43-amino-acid protein involved in cell migration, wound healing, and tissue repair signalling.[1][2]

In plain language, tb-500 peptide (also written as tb 500 or tb500) is studied primarily through a recovery and tissue-repair lens. Thymosin beta-4 is one of the most abundant intracellular proteins in mammalian cells, where it plays a central role in actin polymerisation, cell motility, and tissue remodelling. TB-500 replicates the region of thymosin beta-4 responsible for its actin-binding and cell-migration properties.[1][3]

The research profile spans wound healing, cardiac repair, corneal injury, hair follicle activation, and anti-inflammatory activity. Animal data is extensive and directionally consistent. Human clinical data is limited but emerging, with a 2025 cardiac study providing the first controlled human evidence.[4] For adjacent context, this page pairs naturally with BPC-157 and the BPC-157 vs TB-500 comparison.

Compound Profile

What Does TB-500 Actually Do?

TB-500 is usually evaluated through a recovery-continuity lens. The core action centres on actin regulation: TB-500 sequesters G-actin monomers, promoting the formation of new actin filaments that drive cell migration to injury sites. This is the mechanistic foundation for its tissue-repair signals across multiple organ systems.[1][3]

Useful practical markers from the literature include:

• Wound closure acceleration: faster epithelialisation and granulation tissue formation in dermal, corneal, and cardiac wound models.[3][5][6]
• Cardiac tissue repair: improved ventricular function and reduced scar size in ischaemic heart models, with the first human cardiac data published in 2025.[4][7]
• Anti-inflammatory activity: downregulation of pro-inflammatory cytokines and modulation of inflammatory cell infiltration at injury sites.[2][8]
• Hair follicle activation: thymosin beta-4 stimulates hair growth via stem cell migration and differentiation in mouse models.[9][10]
• Corneal wound healing: accelerated corneal epithelial repair and reduced inflammation following chemical injury, with human clinical interest in ophthalmology.[5][6]

Best framed as support-context for recovery rhythm across tissue types, not a guaranteed structural repair tool. The breadth of tissue responses is notable but the depth of human evidence remains limited.

How TB-500 Works

TB-500 is a synthetic fragment of thymosin beta-4, replicating the 17-23 amino acid sequence (LKKTETQ) that mediates its biological activity. The parent protein thymosin beta-4 is one of the most studied members of the beta-thymosin family and plays fundamental roles in cellular architecture and tissue repair.[1][2]

Key mechanisms identified in the literature:

• Actin polymerisation regulation: TB-500 sequesters G-actin monomers, controlling the balance between monomeric and filamentous actin. This drives cell migration, a prerequisite for wound healing and tissue remodelling in every tissue type studied.[1][3]
• Cell migration promotion: by modulating the actin cytoskeleton, TB-500 promotes directional migration of endothelial cells, keratinocytes, and cardiac progenitor cells toward injury sites.[3][4]
• Angiogenesis: stimulates new blood vessel formation via endothelial cell migration and VEGF-related pathways, supporting nutrient and oxygen delivery to healing tissues.[3][7]
• Anti-inflammatory signalling: downregulates NF-κB-mediated inflammatory responses and reduces pro-inflammatory cytokine production, creating a more favourable environment for tissue repair.[2][8]
• Stem cell activation: in hair follicle models, thymosin beta-4 activates follicular stem cells and promotes their migration and differentiation.[9][10]

The interpretation point that matters: mechanism plausibility does not equal guaranteed outcome. TB-500 has strong mechanistic logic and consistent animal data, but signal quality in any individual context still depends on injury type, timing, and the broader recovery environment.

Injury and Tissue Support Context

Injury and tissue support is TB-500’s primary research domain and where the evidence base is deepest. The parent protein thymosin beta-4 has been studied across dermal wounds, cardiac ischaemia, corneal injury, tendon damage, and musculoskeletal repair models.[1][2][3]

Key findings across tissue types:

• Dermal wound healing: Philp et al. (2004) demonstrated that thymosin beta-4 promotes angiogenesis, accelerates wound closure, and enhances hair follicle development at wound sites in animal models.[3]
• Corneal repair: Sosne et al. (2002) showed thymosin beta-4 promotes corneal wound healing and decreases inflammation following alkali injury, a finding that led to sustained ophthalmological interest and human clinical exploration.[5] A 2025 engineered tandem thymosin peptide further advanced corneal healing outcomes.[6]
• Tendon and soft tissue: orthopaedic review literature identifies TB-500 as one of the most studied injectable peptides in sports medicine contexts, with signals across tendon healing, ligament repair, and soft-tissue recovery.[2]
• Musculoskeletal context: the 2026 orthopaedic review by Rahman et al. positioned thymosin beta-4 among the leading therapeutic peptide candidates for musculoskeletal applications based on cumulative preclinical evidence.[11]

When users say TB-500 “helps repair,” the defensible framing is that it supports the biological conditions for tissue remodelling: cell migration, angiogenesis, and inflammatory modulation. Not guaranteed structural restoration. The animal evidence is consistent and broad, but controlled human tissue-repair trials are only beginning to emerge.

Cardiac Repair Context

Cardiac repair is where TB-500 and thymosin beta-4 have generated the most translational excitement and, recently, the first human clinical data.

The preclinical foundation is substantial: Smart et al. (2007) established that thymosin beta-4 is essential for coronary vessel development and promotes neovascularisation via adult epicardial progenitor cells.[7] Maar et al. (2025) demonstrated thymosin beta-4 modulates cardiac remodelling by regulating ROCK1 expression in adult mammals, reducing fibrosis and improving ventricular function after injury.[8]

The breakthrough: Zhang et al. (2025) published in Cardiovascular Research the first controlled human evidence, showing recombinant human thymosin beta-4 improved ischaemic cardiac dysfunction in both mouse models and patients with acute ST-segment elevation myocardial infarction (STEMI). This is a significant milestone because it moves thymosin beta-4 cardiac research from animal-only to human translational evidence.[4]

Interpretation should stay measured: this is early-stage human data from a single study. But it represents the most advanced clinical evidence for any thymosin beta-4 application and validates the preclinical cardiac repair signals that have accumulated over two decades.

Recovery and Sleep Context

Recovery and sleep relevance for TB-500 is generally downstream: if tissue-stress recovery becomes more stable, total training disruption can fall, which may support steadier sleep quality and better next-session readiness.

In practice, this often appears as fewer interrupted training blocks, lower rebound fatigue, and more predictable recovery rhythm across demanding weeks. The anti-inflammatory mechanisms may contribute to reduced systemic inflammation burden, which can influence sleep architecture indirectly.[2][8]

The practical lens is continuity over time, not one-day symptom swings. For a recovery-focused comparison with the other primary tissue-repair peptide, see the BPC-157 vs TB-500 breakdown.

TB-500 Hair Growth Context

TB-500 hair growth is a consistently searched topic, and the parent protein thymosin beta-4 has genuine hair follicle research behind it.

Philp et al. (2004) demonstrated in FASEB Journal that thymosin beta-4 increases hair growth by activation of hair follicle stem cells.[10] The same group showed thymosin beta-4 promotes hair follicle development alongside angiogenesis and wound healing in animal models.[3] Gao et al. (2015) confirmed thymosin beta-4 induces mouse hair growth via stem cell migration pathways, and a 2016 follow-up explored the molecular mechanisms through which thymosin beta-4 drives follicle cycling.[9]

The evidence is consistent in animal models but no human hair growth trials exist for TB-500 or thymosin beta-4. The mechanistic logic is sound: the same stem cell migration and growth factor pathways that drive wound healing also support hair follicle activation. But translating mouse hair growth data to human outcomes requires caution. Hair growth is biologically plausible but clinically unconfirmed for TB-500.

TB-500 Benefits

TB-500 benefits are strongest when interpreted through evidence-weighted framing:

• Wound healing acceleration: consistent across dermal, corneal, and cardiac wound models in animals. The most replicated finding in the TB-500 literature.[3][5][6]
• Cardiac function improvement: reduced scar size and improved ventricular function in ischaemic models, with first-in-human STEMI data published 2025.[4][7][8]
• Anti-inflammatory activity: downregulation of pro-inflammatory cytokines and NF-κB signalling, creating more favourable repair conditions.[2][8]
• Hair follicle activation: stem cell migration and differentiation in mouse hair growth models. Consistent preclinical signals across multiple studies.[9][10]
• Corneal repair: accelerated epithelial healing and reduced inflammation in corneal injury models, with clinical ophthalmology interest.[5][6]
• Training continuity support: in the practical context, TB-500 is often evaluated by fewer stop-start disruptions, better movement confidence, and more consistent recovery rhythm across training blocks.

Evidence-weighted read: animal tissue-repair data is extensive and consistent. Human cardiac data is emerging. Other human clinical data remains limited. Support-pattern outcomes are plausible, but certainty remains context-dependent.[2][4]

TB-500 Side Effects

For tb-500 side effects intent, the safety profile draws primarily from animal studies and the limited human cardiac data:

• Headache patterns: reported in anecdotal contexts. Not systematically documented in controlled research.
• Nausea or GI discomfort: occasional reports in practical use contexts.
• Injection site reactions: redness, swelling, or discomfort at injection sites. Consistent with most subcutaneous peptide administration.
• Lethargy or fatigue: transient tiredness reported by some users, typically resolving within days.
• Substantial person-to-person variability: individual responses vary considerably, and attribution is difficult when multiple recovery variables change simultaneously.

The 2025 human cardiac study reported thymosin beta-4 was well tolerated in STEMI patients, though this was a specific clinical population receiving specific protocols.[4] Broader human safety profiling for TB-500 at various research concentrations remains limited. Trend-based interpretation over weeks is more reliable than single-day reactions.[2]

Half-Life

For tb-500 half-life queries: TB-500 is commonly discussed with a multi-day persistence context, often cited around 2 to 3 days in practical discussions. The equine pharmacokinetic analysis by Ho et al. (2012) characterised TB-500 detection windows in plasma and urine, providing the most detailed pharmacokinetic data available for this peptide.[12]

Exact human pharmacokinetic certainty is still limited. The peptide’s relatively long half-life compared to smaller peptides like GHK-Cu (which degrades in minutes to hours) is attributed to its larger size (4963 g/mol) and protein-like structure.

Practical takeaway: use half-life as orientation, then judge outcomes by weekly recovery and movement-trend quality rather than strict clock assumptions.

Neuroprotection Context

Neuroprotection is an emerging research area for thymosin beta-4 with recent significant findings. Ou et al. (2026) demonstrated that thymosin beta-4-derived peptides alleviate neuroinflammation and neurite atrophy in both in vitro and in vivo models, suggesting neuroprotective potential through anti-inflammatory CNS pathways.[13]

This emerging neuroprotective profile parallels recent findings in the related peptide GHK-Cu, which has shown neuroprotective signals in Alzheimer’s mouse models. Both peptides share anti-inflammatory and tissue-protective mechanisms, though through distinct pathways. TB-500 neuroprotection data is currently limited to a single study and remains preclinical.

Limits of Current Evidence

• Animal data is extensive and consistent across wound healing, cardiac repair, corneal injury, and hair follicle activation. This breadth is unusual for a single peptide fragment.[1][2][3]
• Human evidence is emerging but limited. The 2025 cardiac STEMI study is the most significant clinical milestone, but it is a single study in a specific population.[4]
• Ophthalmological interest has not yet produced approved therapies. Despite two decades of corneal research, thymosin beta-4 eye treatments remain investigational.[5][6]
• Hair growth data is animal-only. Mouse studies are consistent but human hair trials do not exist.[9][10]
• Attribution weakens quickly when multiple recovery variables shift at once. Short-term perception can overstate confidence versus week-level data.
• Equine doping detection research provides pharmacokinetic data but was designed for regulatory detection, not therapeutic characterisation.[12]

Decision rule: confidence rises when the same pattern repeats under stable conditions. Animal evidence supports mechanism plausibility. Human evidence supports cardiac applications. Other applications remain preclinical.

Verdict

TB-500 is best positioned as a recovery-continuity support candidate with unusually broad preclinical evidence across wound healing, cardiac repair, corneal injury, hair follicle activation, and anti-inflammatory activity. The parent protein thymosin beta-4 has one of the longest and most consistent research trails in the peptide literature.

The 2025 human cardiac data marks a genuine translational milestone. For other applications, the evidence remains preclinical but mechanistically sound. TB-500 tends to fit best when fundamentals are already tight (sleep, load management, rehab structure, nutrition) and outcomes are judged by trend quality, not one-day noise.

For navigation, map this profile to Injury and Tissue Support and Recovery and Sleep, pressure-test with BPC-157 vs TB-500, and cross-reference with BPC-157 and GHK-Cu for the broader tissue-repair peptide landscape.

FAQ

What is TB-500?

TB-500 is a synthetic peptide fragment of thymosin beta-4, a naturally occurring protein involved in cell migration, wound healing, and tissue repair. It corresponds to the active region (amino acids 17-23) responsible for actin regulation and cell motility. TB-500 has been studied across wound healing, cardiac repair, corneal injury, and hair growth contexts.[1][2]

What is thymosin beta-4?

Thymosin beta-4 is a 43-amino-acid protein found abundantly in most mammalian cells. It plays a central role in actin polymerisation, cell migration, and tissue repair. TB-500 is a synthetic version of its active region. The full protein has been studied in cardiac repair, wound healing, corneal injury, and neuroprotection research.[1][3][4]

What are TB-500 benefits?

Research-documented benefits include accelerated wound closure in animal models, improved cardiac function after ischaemic injury (including first human data in STEMI patients), corneal wound healing, hair follicle activation in mice, and anti-inflammatory activity. Human clinical data beyond cardiology remains limited.[2][3][4]

What are TB-500 side effects?

Commonly discussed side effects include headache, nausea, injection site reactions, and transient fatigue. The 2025 human cardiac study reported good tolerability. Broader human safety profiling at various concentrations remains limited. Person-to-person variability is substantial.[2][4]

TB-500 dose and TB-500 dosage: why not listed here?

This page is informational only and does not provide dosing protocols. Dose and dosage intent is valid, but this profile focuses on mechanism context, evidence quality, and risk-aware interpretation. Refer to primary research literature for protocol parameters.

Does TB-500 help with hair growth?

Thymosin beta-4 has consistent animal evidence for hair growth via stem cell activation and migration. Philp et al. (2004) demonstrated hair growth by activation of follicle stem cells, and Gao et al. (2015) confirmed the effect in mouse models. However, no human hair growth trials exist for TB-500 or thymosin beta-4. The evidence is biologically plausible but clinically unconfirmed.[9][10]

TB-500 vs BPC-157: what is the useful comparison?

Both are studied in tissue-repair contexts but via distinct mechanisms. TB-500 operates via actin regulation and cell migration. BPC-157 works through angiogenesis and growth factor pathways with a broader gastric-protective profile. Neither has extensive human clinical data, though TB-500 now has the first cardiac human evidence. See BPC-157 vs TB-500 for a detailed breakdown.[2]

Is TB-500 backed by strong human evidence?

Human evidence is emerging. The 2025 Zhang et al. study in Cardiovascular Research provides the first controlled human cardiac data for thymosin beta-4. Other applications (wound healing, corneal repair, hair growth) remain at preclinical stage. The animal evidence base is extensive but translation to human outcomes outside cardiology is unconfirmed.[4]

TB-500 results: what does that usually mean in practice?

Usually trend-level recovery outcomes: improved movement tolerance, fewer interrupted training sessions, and steadier continuity over weeks rather than instant dramatic change. Confidence is highest when the same pattern repeats under stable conditions over multi-week windows.

Is TB-500 safe?

TB-500 was well tolerated in the 2025 human cardiac study. Beyond that, human safety data is limited. Animal studies across multiple tissue types have not raised significant safety concerns. As with all research peptides, the absence of comprehensive human safety trials means caution is appropriate.[2][4]

References

1. Philp D, et al. Thymosin beta4 promotes angiogenesis, wound healing, and hair follicle development. Mech Ageing Dev. 2004;125(2):113-115. PMID: 15037013.
2. Mayfield CK, et al. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. Am J Sports Med. 2026;54(1):223-229. PMID: 41476424.
3. Philp D. Animal studies with thymosin beta, a multifunctional tissue repair and regeneration peptide. Ann N Y Acad Sci. 2010;1194:81-86. PMID: 20536453.
4. Zhang Y, et al. Recombinant human thymosin beta 4 improves ischemic cardiac dysfunction in mice and patients with acute ST-segment elevation myocardial infarction. Cardiovasc Res. 2025;121(4):cvaf024. PMID: 41229390.
5. Sosne G, et al. Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury. Exp Eye Res. 2002;74(2):293-299. PMID: 11950239.
6. Sosne G. Thymosin beta 4 and the eye: the journey from bench to bedside. Expert Opin Biol Ther. 2018;18(sup1):99-104. PMID: 30063853.
7. Smart N, et al. Thymosin beta-4 is essential for coronary vessel development and promotes neovascularization via adult epicardial progenitors. Ann N Y Acad Sci. 2007;1112:171-188. PMID: 17495252.
8. Maar K, et al. Thymosin Beta-4 Modulates Cardiac Remodeling by Regulating ROCK1 Expression in Adult Mammals. Int J Mol Sci. 2025;26(8):3476. PMID: 40362372.
9. Gao X, et al. Thymosin Beta-4 Induces Mouse Hair Growth. PLoS One. 2015;10(6):e0130040. PMID: 26083021.
10. Philp D, et al. Thymosin beta4 increases hair growth by activation of hair follicle stem cells. FASEB J. 2004;18(2):385-387. PMID: 14657002.
11. Rahman OF, et al. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. JAAOS Glob Res Rev. 2026;10(1):e24.00304. PMID: 41490200.
12. Ho ENM, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin beta-4, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012;1265:1-9. PMID: 23084823.
13. Ou H, et al. Thymosin beta-4-derived peptides alleviate neuroinflammation and neurite atrophy in both in vitro models and in vivo. Int Immunopharmacol. 2026;148:114091. PMID: 41443105.